vx 497 has been researched along with (-)-gallocatechin gallate in 1 studies
| Studies (vx 497) | Trials (vx 497) | Recent Studies (post-2010) (vx 497) | Studies ((-)-gallocatechin gallate) | Trials ((-)-gallocatechin gallate) | Recent Studies (post-2010) ((-)-gallocatechin gallate) |
|---|---|---|---|---|---|
| 25 | 3 | 7 | 19 | 0 | 10 |
| Protein | Taxonomy | vx 497 (IC50) | (-)-gallocatechin gallate (IC50) |
|---|---|---|---|
| Hepatocyte growth factor receptor | Homo sapiens (human) | 10 | |
| Glucose-6-phosphate 1-dehydrogenase | Saccharomyces cerevisiae S288C | 0.23 | |
| Proteasome subunit beta type-5 | Homo sapiens (human) | 0.187 | |
| Alpha-synuclein | Homo sapiens (human) | 3.6 | |
| 6-phosphogluconate dehydrogenase, decarboxylating | Homo sapiens (human) | 1.45 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.121 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 10 | |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.5 | |
| 3-oxoacyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 1.1 | |
| Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein) | Plasmodium falciparum (malaria parasite P. falciparum) | 0.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT | 1 |
1 review(s) available for vx 497 and (-)-gallocatechin gallate
| Article | Year |
|---|---|
Drugs for the Treatment of Zika Virus Infection.
Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection | 2020 |